ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS
内毒素耐受作为免疫麻痹的模型
基本信息
- 批准号:6127300
- 负责人:
- 金额:$ 25.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-03-15 至 2004-02-28
- 项目状态:已结题
- 来源:
- 关键词:apoptosis bacteria infection mechanism biomarker blood toxicology candidiasis cellular immunity clinical research disease /disorder model endotoxins heart /lung bypass human subject immune tolerance /unresponsiveness immunoregulation interferon gamma interleukin 12 laboratory mouse natural killer cells nosocomial infections pathologic process postoperative complications prognosis tumor necrosis factor alpha
项目摘要
DESCRIPTION (adapted from applicant's abstract) The applicants propose to study
the pathogenesis and biologic significance of injury-induced defects in the
innate cellular immune response. These include studies of both experimental
endotoxin tolerance in mice and clinical immune paralysis in cardiac surgery
patients. Endotoxin tolerance is induced by repeated exposures to
lipopolysaccharide (endotoxin) and results in reduced synthesis of
pro-inflammatory cytokines to microbial stimuli. Immune paralysis is
phenotypically similar, but is a clinical phenomenon induced by sepsis or
trauma. They hypothesize that endotoxin tolerance and immune paralysis disrupt
the interdependent production and synergistic anti-microbial activities of
TNF-alpha, IL-12 and IFN-gamma that mediate the innate cellular immune
response. Their first goal is to use the well-characterized mouse model of
endotoxin tolerance to identify mechanisms that mediate the immune defects of
endotoxin tolerance and enhance susceptibility to infection. They will then
identify interventions that prevent or reverse these immune deficiencies.
Preliminary data already indicate immune cell depletion is a mechanism for
injury-induced cytokine deficiency and identify a 10- to 10,000-fold enhanced
susceptibility to candidiasis during endotoxin tolerance. The applicants'
second goal is to study the biologic basis and epidemiologic consequence of
immune paralysis in cardiac surgery patients, with a long term goal of
developing clinical interventions to prevent immune paralysis. The specific
aims of this proposal are: 1) Identify molecular and/or cellular defects in the
innate immune response of endotoxin tolerant mice. 2) Determine if the
defective innate immunity of endotoxin tolerance enhances susceptibility to
common nosocomial pathogens. 3) Use these findings to rationally design drug or
cytokine therapies that prevent the immune defects of endotoxin tolerance and
thereby reduce susceptibility to nosocomial superinfection. 4) Characterize
comparable cytokine and cellular defects in hospitalized patients following
cardiac surgery and identify immune phenotypic markers predictive of
post-operative infections. Studies of the immune pathogenesis of infectious
susceptibility in endotoxin tolerant mice are likely to suggest cytokine- or
anti-apoptosis-based therapies for clinical immune paralysis. This is a
clinically desirable goal, as the preservation or enhancement of innate
immunity against nosocomial infections in injured patients may significantly
reduce hospital morbidity, costs, antibiotic use and the selection of
antibiotic-resistant pathogens.
描述(改编自申请人摘要)申请人拟参加学习
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FREDERICK P. HEINZEL其他文献
FREDERICK P. HEINZEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FREDERICK P. HEINZEL', 18)}}的其他基金
ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS
内毒素耐受作为免疫麻痹的模型
- 批准号:
6632103 - 财政年份:2000
- 资助金额:
$ 25.41万 - 项目类别:
ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS
内毒素耐受作为免疫麻痹的模型
- 批准号:
6511013 - 财政年份:2000
- 资助金额:
$ 25.41万 - 项目类别:
ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS
内毒素耐受作为免疫麻痹的模型
- 批准号:
6362421 - 财政年份:2000
- 资助金额:
$ 25.41万 - 项目类别:
INTERLEUKIN-12 AS IMMUNOTHERAPY IN LEISHMANIASIS
INTERLEUKIN-12 作为利什曼病的免疫疗法
- 批准号:
2071988 - 财政年份:1994
- 资助金额:
$ 25.41万 - 项目类别:
INTERLEUKIN 12 FUNCTION DURING MURINE LEISHMANIASIS
鼠利什曼病期间白细胞介素 12 的功能
- 批准号:
2057400 - 财政年份:1994
- 资助金额:
$ 25.41万 - 项目类别:
INTERLEUKIN 12 FUNCTION DURING MURINE LEISHMANIASIS
鼠利什曼病期间白细胞介素 12 的功能
- 批准号:
2057399 - 财政年份:1994
- 资助金额:
$ 25.41万 - 项目类别:
INTERLEUKIN 12 FUNCTION DURING MURINE LEISHMANIASIS
鼠利什曼病期间白细胞介素 12 的功能
- 批准号:
2057398 - 财政年份:1994
- 资助金额:
$ 25.41万 - 项目类别:
INTERLEUKIN 12 AS IMMUNOTHERAPY IN LEISHMANIASIS
白细胞介素 12 作为利什曼病的免疫治疗
- 批准号:
6169986 - 财政年份:1994
- 资助金额:
$ 25.41万 - 项目类别:
INTERLEUKIN 12 AS IMMUNOTHERAPY IN LEISHMANIASIS
白细胞介素 12 作为利什曼病的免疫治疗
- 批准号:
2886914 - 财政年份:1994
- 资助金额:
$ 25.41万 - 项目类别:
INTERLEUKIN-12 AS IMMUNOTHERAPY IN LEISHMANIASIS
INTERLEUKIN-12 作为利什曼病的免疫疗法
- 批准号:
2071989 - 财政年份:1994
- 资助金额:
$ 25.41万 - 项目类别: